` ELDN (Eledon Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

ELDN
vs
S&P 500

Over the past 12 months, ELDN has outperformed S&P 500, delivering a return of +27% compared to the S&P 500's +17% growth.

Stocks Performance
ELDN vs S&P 500

Loading
ELDN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ELDN vs S&P 500

Loading
ELDN
S&P 500
Difference
www.alphaspread.com

Performance By Year
ELDN vs S&P 500

Loading
ELDN
S&P 500
Add Stock

Competitors Performance
Eledon Pharmaceuticals Inc vs Peers

S&P 500
ELDN
ABBV
CYTH
AMGN
GILD
Add Stock

Eledon Pharmaceuticals Inc
Glance View

Market Cap
216.8m USD
Industry
Biotechnology

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

ELDN Intrinsic Value
2.09 USD
Overvaluation 42%
Intrinsic Value
Price
Back to Top